SCHEMBL1483567

SCHEMBL1483567

O=S(=O)([O-])c1ccc(N=C=S)cc1.[Na+]

nearest known ligand 0.66

Known targets — ChEMBL curated mechanism

ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 known ✓ P00915 2/20 0.66
CA2 known ✓ P00918 2/20 0.66
P2RY6 known ✓ Q15077 3/20 0.47
THRB known ✓ P10828 1/20 0.36
RAD51 Q06609 4/20 0.56
TDP1 Q9NUW8 4/20 0.56
HSD17B10 Q99714 3/20 0.56
MAPT P10636 3/20 0.56
ALDH1A1 P00352 3/20 0.56
KDM4E B2RXH2 2/20 0.56
USP2 O75604 2/20 0.56
LTA P01374 2/20 0.56
CYP3A4 P08684 2/20 0.56
HPGD P15428 2/20 0.56
P2RX3 P56373 2/20 0.56
MIF P14174 2/20 0.46
PLCG1 P19174 1/20 0.42
CA9 Q16790 1/20 0.42
RAD1 O60671 1/20 0.41
KEAP1 Q14145 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL3903041 0.98 CA1 (0.63) CA1CA2RAD51TDP1HSD17B10
SCHEMBL483832 0.83 CA1 (0.70) CA1CA2RAD51TDP1HSD17B10
SCHEMBL4350712 0.82 RAD51 (0.55) CA1CA2RAD51TDP1HSD17B10
SCHEMBL3895085 0.82 RAD51 (0.50) CA1CA2RAD51TDP1HSD17B10
SCHEMBL31148855 0.81 CYP3A4 (0.48) CA1CA2RAD51TDP1HSD17B10
SCHEMBL10907354 0.80 RAD51 (0.53) CA1CA2RAD51TDP1HSD17B10
SCHEMBL668791 0.79 CA1 (0.66) CA1CA2RAD51TDP1HSD17B10
SCHEMBL31315339 0.79 CA1 (0.66) CA1CA2RAD51TDP1HSD17B10
SCHEMBL2891113 0.79 CA1 (0.66) CA1CA2RAD51TDP1HSD17B10
SCHEMBL6196292 0.79 CA1 (0.66) CA1CA2RAD51TDP1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3543226-B1 NOVEL IMAGING COMPOSITION AND USES THEREOF UNIV MELBOURNE (AU) 2024-03-06 EP disclosed
US-11123316-B2 Imaging composition and uses thereof THE UNIVERSITY OF MELBOURNE (AU) 2021-09-21 US disclosed
US-20200246286-A1 NOVEL IMAGING COMPOSITION AND USES THEREOF THE UNIVERSITY OF MELBOURNE (AU) 2020-08-06 US disclosed
US-10653649-B2 Imaging composition and uses thereof THE UNIVERSITY OF MELBOURNE (AU) 2020-05-19 US disclosed
EP-3543226-A1 NOVEL IMAGING COMPOSITION AND USES THEREOF The University of Melbourne (AU) 2019-09-25 EP disclosed
US-10398660-B2 Imaging composition and uses thereof THE UNIVERSITY OF MELBOURNE (AU) 2019-09-03 US disclosed
EP-3207027-B1 NOVEL IMAGING COMPOSITION AND USES THEREOF UNIV MELBOURNE (AU) 2019-06-19 EP disclosed
US-20190099392-A1 NOVEL IMAGING COMPOSITION AND USES THEREOF THE UNIVERSITY OF MELBOURNE (AU) 2019-04-04 US disclosed
US-9994444-B2 Bridged polycyclic compound based compositions for the inhibition and amelioration of disease ALLACCEM, INC. (US) 2018-06-12 US disclosed
US-9980930-B2 Imaging composition and uses thereof THE UNIVERSITY OF MELBOURNE (AU) 2018-05-29 US disclosed
US-6528528-B2 Inhibitors of 15-lipoxygenase, inhibiting chemotaxis of monocytes WARNER-LAMBERT COMPANY 2003-03-04 US disclosed
WO-2002049413-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2002-06-27 WO disclosed
US-20010031874-A1 Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis CONNOR DAVID THOMAS (US) 2001-10-18 US disclosed
US-6268387-B1 INHIBITORS OF THE ENZYME 15-LIPOXYGENASE AND ARE INHIBITORS OF MONOCYTE CHEMOTAXIS. WARNER-LAMBERT COMPANY 2001-07-31 US disclosed
EP-1042276-A1 THIOUREA COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS WARNER-LAMBERT COMPANY LLC (US) 2000-10-11 EP disclosed
WO-1999032433-A1 THIOUREA AND BENZAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS WARNER-LAMBERT COMPANY (US) 1999-07-01 WO disclosed
US-5280015-A 2-substituted adenosines and 2-substituted adenosine 5'-carboxamides THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1994-01-18 US disclosed
US-5045478-A Vesicles and use thereof in an assay BECTON DICKINSON AND COMPANY (US) 1991-09-03 US disclosed
US-4717676-A Vesicles and use thereof in an assay BECTON DICKINSON AND COMPANY (US) 1988-01-05 US disclosed
US-4610954-A ANTIFOGGING AGENTS FUJI PHOTO FILM CO., LTD. (JP) 1986-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200246286-A1 NOVEL IMAGING COMPOSITION AND USES THEREOF CA13, CA14, CA12 CA1 4/4885CA2 33/4885P2RY6 4665/4885
US-20010031874-A1 Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis TPMT, CTH, CBS CA1 4089/4885CA2 2286/4885P2RY6 311/4885
US-10653649-B2 Imaging composition and uses thereof CA13, CA14, CA12 CA1 4/4885CA2 30/4885P2RY6 4489/4885
US-10398660-B2 Imaging composition and uses thereof CA13, CA14, CA12 CA1 4/4885CA2 37/4885P2RY6 4437/4885
US-20190099392-A1 NOVEL IMAGING COMPOSITION AND USES THEREOF CA13, CA14, CA12 CA1 4/4885CA2 33/4885P2RY6 4665/4885
US-11123316-B2 Imaging composition and uses thereof CA13, CA14, CA12 CA1 4/4885CA2 30/4885P2RY6 4489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.